Oxford University COVID-19 vacine 'well tolerated in older adults'

Grant Boone
November 20, 2020

AstraZeneca, which developed its vaccine with researchers at Britain's Oxford University, is testing its vaccine in Phase 3 clinical trials around the world - the last stage before seeking regulatory approval.

"Immunisation with ChAdOx1 nCoV-19 results in the development of neutralising antibodies against SARS-CoV-2 in nearly 100 per cent of participants including older adults without severe co-morbidities, with higher levels in boosted compared with non-boosted groups".

With the exception of one company, none of the COVID-19 vaccine developers have committed to treating IP any differently than the status quo.

They show that older adults aged 56-69 and over 70 had a similar immune response to younger adults aged 18-55.

The T-cell response - another measure of how well the immune system responds - peaked two weeks after the first dose of the vaccine, regardless of age. T-cell response occurred within 14 days of the first dose of vaccination, and antibody response occurred within 28 days of the booster dose of vaccination.

The results of the peer-reviewed study were published Thursday in the Lancet, an global medical journal.

What's more, the Trump administration has a deal with AstraZeneca, paying $1.2 billion in exchange for 300 million doses of the vaccine for the United States if it is shown to be effective.

Hey look, glow-in-the-dark PowerBeats
They also have an Apple H1 chip which lets it seamlessly connect to Apple devices and access to "Hey Siri" for hands-free control. Unlike the new Beats Flex, these still charge over Lightning as well, and include a short USB-A to Lightning cable for charging.

"It's critical to have diverse participants in a coronavirus vaccine trial so we know it is effective for populations that are often underrepresented in research", said XinQi Dong, who's directing community recruitment for the Johnson & Johnson trial.

The experimental vaccines are undergoing Phase 3 clinical trials overseas that have recruited almost 60,000 people, and blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, the article said citing Liu, without breaking down the numbers for each vaccine.

Russian Federation has also reached a grim milestone, surpassing 2 million total coronavirus cases on Thursday after reporting 23,610 new cases over a 24-hour period, including 463 deaths. Instead, it looked at safety indicators and the body's immune response.

"That is a concern", said Thomas Campbell, associate dean for clinical research at the University of Colorado, of the low antibody levels in Sinovac's Phase 2 trial. "They must also be safe, effective in preventing disease and/or transmission, and provide at least six months of protection for people frequently exposed to the virus - such as healthcare workers".

That was lower than antibodies from vaccine trials by world leaders Pfizer Inc. and Moderna Inc., which are using a different vaccine technology, and which recorded antibody levels in patients that were about the same as those who had contracted the virus.

Gilbert added that they're looking at giving people two vaccine doses and then monitoring how well those responses are maintained.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER